Eutilex Co.,Ltd. Logo

Eutilex Co.,Ltd.

Develops immunotherapeutics for cancers and autoimmune diseases via T-cell/antibody tech.

263050 | KO

Overview

Corporate Details

ISIN(s):
KR7263050007
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산디지털1로 58 408호 (가산동, 에이스한솔타워), 서울특별시

Description

Eutilex Co., Ltd. is a biotechnology company focused on the research and development of immunotherapeutics for cancers and autoimmune diseases. The company's core approach involves selecting targets that enhance or suppress human immune responses. Its pipeline is centered on three primary technology platforms: T-cell therapy, antibody therapy, and CAR-T cell therapy. Key development programs include adoptive T-cell therapies, such as those based on 4-1BB cytotoxic T lymphocytes (CTL), and various immunomodulatory antibody therapeutics designed to treat a range of incurable diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-03-08 00:00
의결권대리행사권유참고서류
Korean 176.1 KB
2023-03-08 00:00
주식매수선택권부여에관한신고
Korean 13.2 KB
2023-02-15 00:00
투자판단관련주요경영사항(EU307(GPC3-IL18 CAR-T 치료제) 간세포암 대상 제1상 임상시험계획서 승인)
Korean 9.0 KB
2023-02-09 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.8 KB
2023-02-06 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.5 KB
2023-01-06 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.5 KB
2023-01-02 00:00
투자판단관련주요경영사항(EU103(항VSIG4 항체치료제) 고형암 대상 제1상 임상시험계획서(IND) 신청)
Korean 8.2 KB
2022-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2022-11-14 00:00
분기보고서 (2022.09)
Korean 1.2 MB
2022-11-04 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.1 KB
2022-10-07 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.3 KB
2022-10-04 00:00
기타경영사항(자율공시)(항 4-1BB 항체치료제 EU101 일본 특허권 취득(분할특허))
Korean 6.6 KB
2022-09-30 00:00
기업설명회(IR)개최
Korean 7.5 KB
2022-09-29 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.5 KB
2022-09-15 00:00
기업설명회(IR)개최
Korean 6.9 KB

Automate Your Workflow. Get a real-time feed of all Eutilex Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Eutilex Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Eutilex Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.